Idasanutlin is a potent small-molecule inhibitor of the BCL-2 family that targets BCL-2 and BCL-xL proteins to induce apoptosis in cancer cells and is currently investigated in clinical trials for treating… Read more
Idasanutlin is a potent small-molecule inhibitor of the BCL-2 family that targets BCL-2 and BCL-xL proteins to induce apoptosis in cancer cells and is currently investigated in clinical trials for treating hematological malignancies, such as acute myeloid leukemia, non-Hodgkin's lymphoma, and recurrent plasma cell myeloma. This category features high-quality reference standards, including the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these materials for rigorous analytical testing, impurity profiling, and method validation to ensure the accuracy and reliability of drug substance analysis. By providing consistent standards for comparison, these compounds facilitate the development and quality control of Idasanutlin throughout the pharmaceutical research and manufacturing process.